- Home
- DKNG vs NTRA Comparison
DKNG vs NTRA Comparison
Compare DKNG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKNG
- NTRA
- Stock Information
- Founded
- DKNG N/A
- NTRA 2003
- Country
- DKNG United States
- NTRA United States
- Employees
- DKNG N/A
- NTRA N/A
- Industry
- DKNG Services-Misc. Amusement & Recreation
- NTRA Medical Specialities
- Sector
- DKNG Consumer Discretionary
- NTRA Health Care
- Exchange
- DKNG Nasdaq
- NTRA Nasdaq
- Market Cap
- DKNG 23.8B
- NTRA 27.0B
- IPO Year
- DKNG N/A
- NTRA 2015
- Fundamental
- Price
- DKNG $31.68
- NTRA $238.04
- Analyst Decision
- DKNG Strong Buy
- NTRA Strong Buy
- Analyst Count
- DKNG 28
- NTRA 16
- Target Price
- DKNG $47.71
- NTRA $224.88
- AVG Volume (30 Days)
- DKNG 18.6M
- NTRA 1.8M
- Earning Date
- DKNG 11-06-2025
- NTRA 11-06-2025
- Dividend Yield
- DKNG N/A
- NTRA N/A
- EPS Growth
- DKNG N/A
- NTRA N/A
- EPS
- DKNG N/A
- NTRA N/A
- Revenue
- DKNG $5,458,104,000.00
- NTRA $2,116,676,000.00
- Revenue This Year
- DKNG $33.29
- NTRA $25.70
- Revenue Next Year
- DKNG $20.08
- NTRA $15.42
- P/E Ratio
- DKNG N/A
- NTRA N/A
- Revenue Growth
- DKNG 18.50
- NTRA 38.17
- 52 Week Low
- DKNG $26.23
- NTRA $125.38
- 52 Week High
- DKNG $53.61
- NTRA $240.40
- Technical
- Relative Strength Index (RSI)
- DKNG 51.90
- NTRA 82.14
- Support Level
- DKNG $29.09
- NTRA $195.14
- Resistance Level
- DKNG $30.61
- NTRA $212.21
- Average True Range (ATR)
- DKNG 1.53
- NTRA 9.35
- MACD
- DKNG 0.44
- NTRA 2.78
- Stochastic Oscillator
- DKNG 91.42
- NTRA 96.00
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 28 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.